

## Chapter 5

# GWAS as the Detective to Find Genetic Contribution in Diseases

**Simanti Bhattacharya**  
*University of Kalyani, India*

**Amit Das**  
*University of Kalyani, India*

### ABSTRACT

*Genome-wide association study (GWAS) is a powerful method to understand the complex association of variant in gene and disease phenotype. With the approach of GWAS, the traditional “one gene to one disease” belief has been taken to another dimension where a rather complex scenario of many possible causal agent (polymorphisms) behind disease onset is explicitly explored. It also gives the liberty to monitor the difference at each point of DNA for each individual in the sample. GWAS is powered with genome mapping projects and depends on stringent statistical analysis that detects the association of polymorphisms to disease phenotype after comparing the samples collected from afflicted and un-afflicted population. However, this method also has its own limitations. But with careful experiment design and unbiased analysis this GWAS, in near future, will become a new edge technology to decipher the disease mechanism so that effective therapeutics, tailored for specific cases can be developed.*

### INTRODUCTION

In the era of unprecedented advancement in medical and technological sciences, Garrod A.E., a physician to the Hospital of Sick Children, in the year of 1902, reported a case of alkaptonuria that he described as “not the manifestation of disease but is rather of the nature of an alternative course of metabolism...”. That was the first report where the possibility of underlying “molecular evidence” behind human disease came in the lime light. Human diseases and their genetic contribution share a complex and intricate relationship, yet to be explored fully. For few cases, phenotypes (diseased condition) could directly be

DOI: 10.4018/978-1-5225-7489-7.ch005

associated with gene, experimentally, whereas a large number of genetic associations behind disease state remained hidden.

That called for a situation where mapping of gene knowledge between afflicted and un-afflicted individuals can be mapped to find out the difference at each point (each nucleotide position or *allele* or *variant*) and the number of occurrences of the mismatched alleles in the diseased individuals (*allelic frequency*) with an assumption that if any allele has higher frequency to appear in the diseased individual then that is associated with the diseased trait. That can be translated as ‘scan through entire gene’ for gene to disease relation mapping or rather, as genetic language, *Genome Wide Association Study* (GWA or GWAS).

These GWAS data not only provide us with the information on the disease association with the gene level knowledge but also enable a deeper understanding of the entire scenario generating a landscape of gene with its minute changes that can be extrapolated to genes coding (impact on protein production) or non-coding regions (impact on protein production regulation), the transcription factor binding sites (regulating transcription), epigenetic modification probabilities (regulation in genetic coding), pathways involved (visualizing the upstream or downstream possible effects) extending to heritability of the diseases. These all impose final impact on the phenotype which is nothing but the diseased state to us. Thus, insight generated with GWAS leads us to understand the actual reason or mechanism behind disease onset that, in turn, guides scientists to find novel druggable targets for more efficient medications or some times, to look for personalized medications (Bush & Moore, 2012).

With the completion of Human Genome Project (human DNA sequence) in 2003 (International HapMap Consortium, 2003) and the International Hapmap project (haplotype map of the human genome) in 2005, scientists are well-equipped with resources to correlate genetic contribution to disease onset. Success of the GWAS reflects in identifying the genetic factor contributing to Parkinson’s disease, Crohn’s disease, type 2 diabetes and obesity to name a few. These GWAS data can also be accessed through various repositories. However, its smaller variant size, unavailability of replicated reports, smaller population size under study stand as limiting factors to uncover a larger portion of genetic information to understand properly. With the rapid advancement in research, these limitations will be overcome to generate a better understanding of the entire scenario of disease with GWAS concept.

## **BACKGROUND**

Life material nucleus i.e. DNA is composed of four basic entities and they are: the purines: Adenine (A), Guanine (G) and the pyrimidines: Cytosine and Thymine (T) arranged in a specific pattern that carries information of life. DNA is double helical element where these purines and pyrimidines pair up with each other (A with T and C with G). The complex of different DNA stabilizing and regulatory molecules (protein, RNA etc) along with DNA is collectively known as Genome. Since not only the presence of these basic entities but also their relative position is crucial to maintain the information for life and its sustainability, small variation of these elements (mutation or polymorphism or SNPs) at any of the otherwise conserved position on DNA has been found to bring change in the system. In Pre-GWAS (Ertekin-Taner, 2010) era researchers managed to characterize the genetic association behind disease that followed a Mendelian pattern of inheritance that largely depended on generation wise co-segregation of causal variants with marker alleles that simply followed Hardy-Weinberg Equilibrium. Cause to genetic variation was thought to be chromosomal cross over at chiasmata during meiosis. To explain, suppose,

10 more pages are available in the full version of this document, which may be purchased using the "Add to Cart" button on the publisher's webpage:

[www.igi-global.com/chapter/gwas-as-the-detective-to-find-genetic-contribution-in-diseases/213584](http://www.igi-global.com/chapter/gwas-as-the-detective-to-find-genetic-contribution-in-diseases/213584)

## Related Content

---

### The Optimal Workforce Staffing Solutions With Random Patient Demand in Healthcare Settings

Alexander Kolker (2019). *Advanced Methodologies and Technologies in Medicine and Healthcare* (pp. 158-174).

[www.irma-international.org/chapter/the-optimal-workforce-staffing-solutions-with-random-patient-demand-in-healthcare-settings/213594](http://www.irma-international.org/chapter/the-optimal-workforce-staffing-solutions-with-random-patient-demand-in-healthcare-settings/213594)

### Bioinformatics

Mark A. Ragan (2019). *Advanced Methodologies and Technologies in Medicine and Healthcare* (pp. 1-14).

[www.irma-international.org/chapter/bioinformatics/213579](http://www.irma-international.org/chapter/bioinformatics/213579)

### Research on Assessing Lidocaine, Ketamine, and Dexamethasone for Airway Complications

R. M. Mulla, V. M. Joshi, P. B. Patil and Kiran Kumar Thoti (2024). *Advancements in Clinical Medicine* (pp. 92-105).

[www.irma-international.org/chapter/research-on-assessing-lidocaine-ketamine-and-dexamethasone-for-airway-complications/346193](http://www.irma-international.org/chapter/research-on-assessing-lidocaine-ketamine-and-dexamethasone-for-airway-complications/346193)

### Case History for the Pediatric Eye Examination

Amy Moy (2022). *The Pediatric Eye Exam Quick Reference Guide: Office and Emergency Room Procedures* (pp. 1-19).

[www.irma-international.org/chapter/case-history-for-the-pediatric-eye-examination/296156](http://www.irma-international.org/chapter/case-history-for-the-pediatric-eye-examination/296156)

### Fundus Examination in Pediatric Patients: Direct Ophthalmoscope and PanOptic Ophthalmoscope

Alanna Khattar (2022). *The Pediatric Eye Exam Quick Reference Guide: Office and Emergency Room Procedures* (pp. 270-280).

[www.irma-international.org/chapter/fundus-examination-in-pediatric-patients/296169](http://www.irma-international.org/chapter/fundus-examination-in-pediatric-patients/296169)